2013 - 2021

Targeting STAT5-regulated Transcription in Myeloid Neoplasms.

The project part leader, Richard Moriggl, is Deputy Speaker of this SFB and was Director of the Ludwig Boltzmann Institute for Cancer Research (LBI-CR) in Vienna. He is a basic cancer researcher and has a major interest and focus in STAT5 expression and function in hematopoietic neoplasms, including CML. During the past few years, Richard has developed concepts to convert or block oncogenic STAT5 in leukemic cells. In addition, the group was able to show that STAT5 forms oncogenic tetramers, and is expressed and exhibits specific functions in both the nuclear and cytoplasmic compartment of leukemic cells. In the SFB the deputy speaker and his team studied the expression, role, and function of STAT5 in JAK2-mutated MPN and Ph+ CML, with the major aim to identify druggable sites on STAT5 and to block STAT5-functions through site-specific targeting approaches.